YL202 should be intravenously infused

DRUG2 trials

Sponsors

MediLink Therapeutics (Suzhou) Co., Ltd.

Conditions

Breast CancerHNSCCLocally Advanced or Metastatic Breast CancerLocally Advanced or Metastatic Solid TumorsNSCLC

Phase 2

A Study of YL202 in Selected Patients With Advanced Solid Tumors

RecruitingNCT06107686

MediLink Therapeutics (Suzhou) Co., Ltd.Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors +1

Start: 2023-12-15End: 2028-11-30Target: 200Updated: 2025-11-26

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

RecruitingNCT06439771

MediLink Therapeutics (Suzhou) Co., Ltd.Locally Advanced or Metastatic Breast Cancer

Start: 2024-04-23End: 2028-07-29Target: 180Updated: 2026-07-17

Related Papers

BNT326-01: A Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig (anti-PD-L1 × VEGF bsAb) in patients with advanced solid tumors.

Journal of Clinical Oncology2026-05-28

Abstract PS1-08-05: First disclosure of efficacy and safety data for YL202/BNT326 (HER3 antibody-drug conjugate [ADC]) in advanced or metastatic HR+/HER2 null and HER2-low breast cancer: Phase 2 trial results

Clinical Cancer Research2026-02-17